Despite tremendous efforts, the clinical prognosis of pancreatic ductal adenocarcinoma (
PDAC
) remains disappointing. There is an urgent need to develop more effective treatment strategies to improve the prognosis of patients with
PDAC
. In this study, we evaluate the anti‐
PDAC
effects of
LY
‐1816, a new multikinase inhibitor developed by us. In in vitro assays,
LY
‐1816 showed significant inhibitory effects on the proliferation, migration, and invasion of human
PDAC
cells, and induced
PDAC
cell apoptosis. Western blot analysis revealed that
LY
‐1816 markedly suppressed the Src signaling, and downregulated the expression of
FOSL
1;
FOSL
1
is an oncogene vulnerability in
KRAS
‐driven pancreatic cancer. In in vivo models of
PDAC
xenografts (Aspc‐1 and Bxpc‐3),
LY
‐1816 showed more potent antitumor activity than dasatinib and gemcitabine. Moreover, mice treated with
LY
‐1816 showed a much more significant survival advantage in a metastatic model of
PDAC
compared with those treated with vehicle, dasatinib, or gemcitabine. These results provide effective support for the subsequent clinical evaluation of
LY
‐1816 in the treatment of
PDAC
.